Mechanism of action of Xiayuxue decoction in inhibiting liver fibrosis by regulating glial cell line-derived neurotrophic factor

Wei ZHANG; Guangyue YANG; Dongxiao SHEN; Wenting MA; Le TAO; Liu WU; Ping YAN; Cheng LIU

doi:10.3969/j.issn.1001-5256.2021.03.015

Volume 37 Issue 3

Mar. 2021

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(3): 575-581

PDF( 2815 KB)

Mechanism of action of Xiayuxue decoction in inhibiting liver fibrosis by regulating glial cell line-derived neurotrophic factor

DOI: 10.3969/j.issn.1001-5256.2021.03.015

a.
Laboratory of Liver Diseases of Experimental Center, Putuo Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China
b.
Department of Infectious Diseases, Putuo Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China

Received Date: 2020-09-11
Accepted Date: 2020-11-05
Published Date: 2021-03-20

Abstract

Abstract

Objective To investigate whether Xiayuxue decoction exerts an anti-liver fibrosis effect by inhibiting glial cell line-derived neurotrophic factor (GDNF). Methods A total of 24 C57BL/6 mice were randomly divided into control group, model group, and Xiayuxue decoction group. The mice in the model group and the Xiayuxue decoction group were given intraperitoneal injection of 10% CCl₄, and those in the Xiayuxue decoction group were given 0.4678 g/kg Xiayuxue decoction by gavage since week 4. The liver function parameters alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured, and liver histopathology was observed. Immunohistochemistry was used to measure the protein expression of alpha-smooth muscle actin (α-SMA) and GDNF. GFP-Col-HSC and human primary hepatic stellate cells (HSCs) were treated with GDNF (10 ng/ml), and HSC activation was measured. A one-way analysis of variance was used for comparison of continuous data between multiple groups, and the least significant difference t-test was used for further comparison between two groups. Results Compared with the control group, the model group had significant increases in the levels of ALT and AST, and compared with the model group, the Xiayuxue decoction group had significant reductions in the levels of ALT and AST (all P < 0.01). Liver histopathology showed that the model group had marked inflammatory cell infiltration and formation of fibrous septa by proliferated collagen fibers, and the Xiayuxue decoction group had loose fibrous septa and alleviated inflammatory cell infiltration. Immunohistochemistry showed that compared with the control group, the model group had significant increases in the expression of α-SMA and GDNF (both P < 0.01), which were observed in fibrous septa, and compared with the model group, the Xiayuxue decoction group had significant reductions in the expression of α-SMA and GDNF (both P < 0.05). Western blotting showed that the control group had relatively low expression of GDNF in liver tissue, the formation of liver fibrosis at week 6 of CCl₄ modeling, and an around 10-fold increase in the expression of GDNF, and the Xiayuxue decoction group had significantly inhibited protein expression of GDNF (P < 0.01); there were significant increases in the expression of α-SMA and collagen type I α1 (Col1) in mice with liver fibrosis, with significant reductions in α-SMA and Col1 after treatment with Xiayuxue decoction (all P < 0.01). The in vitro experiment showed that GDNF induced the significant increases in the protein expression of α-SMA and Col1 in HSCs, which was significantly inhibited by Xiayuxue decoction (all P < 0.01). Conclusion The expression of GDNF is significantly upregulated in the formation of liver fibrosis. GDNF can induce HSC activation, and Xiayuxue decoction can exert an anti-liver fibrosis effect by inhibiting GDNF.
- Liver Cirrhosis,
- Xia-Yu-Xue Decoction,
- Glial Cell Line-Derived Neurotrophic Factor

FullText(HTML)

References(19)

References

[1]	SCHUMACHER JD, KONG B, WU J, et al. Direct and indirect effects of Fibroblast Growth Factor (FGF)15 and FGF19 on liver fibrosis development[J]. Hepatology, 2020, 71(2): 670-685. DOI: 10.1002/hep.30810
[2]	SHI N, CHEN XL, WU H, et al. Role of hepatic lymphangiogenesis in the progression of liver fibrosis[J]. J Clin Hepatol, 2020, 36(9): 2079-2082. (in Chinese. DOI: 10.3969/j.issn.1001-5256.2020.09.038 石纳, 陈修利, 吴昊, 等. 肝脏淋巴管新生在肝纤维化进展中的作用[J]. 临床肝胆病杂志, 2020, 36(9): 2079-2082. DOI: 10.3969/j.issn.1001-5256.2020.09.038
[3]	XIANG J, ZHANG N, SUN H, et al. Disruption of SIRT7 increases the efficacy of checkpoint inhibitor via MEF2D regulation of programmed cell death 1 ligand 1 in hepatocellular carcinoma cells[J]. Gastroenterology, 2020, 158(3): 664-678. e24. DOI: 10.1053/j.gastro.2019.10.025
[4]	DONNELLY CR, SHAH AA, MISTRETTA CM, et al. Biphasic functions for the GDNF-Ret signaling pathway in chemosensory neuron development and diversification[J]. Proc Natl Acad Sci U S A, 2018, 115(3): e516-e525. DOI: 10.1073/pnas.1708838115
[5]	TAO L, MA W, WU L, et al. Glial cell line-derived neurotrophic factor (GDNF) mediates hepatic stellate cell activation via ALK5/Smad signalling[J]. Gut, 2019, 68(12): 2214-2227. DOI: 10.1136/gutjnl-2018-317872
[6]	TAO L, ZHANG J, YAN P, et al. Clinical observation of the effects of supplemented discharging blood stasis decoction on chronic viral hepatitis B[J]. Henan Tradit Chin Med, 2017, 37(11): 1946-1949. (in Chinese. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZY201711026.htm 陶乐, 张洁, 严萍, 等. 加味下瘀血汤治疗慢性乙型病毒性肝炎临床观察[J]. 河南中医, 2017, 37(11): 1946-1949. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZY201711026.htm
[7]	LIU C, YUAN X, TAO L, et al. Xia-yu-xue decoction (XYXD) reduces carbon tetrachloride (CCl₄)-induced liver fibrosis through inhibition hepatic stellate cell activation by targeting NF-κB and TGF-β1 signaling pathways[J]. BMC Complement Altern Med, 2015, 15: 201. DOI: 10.1186/s12906-015-0733-1
[8]	MA W, TAO L, ZHANG W, et al. Xia-Yu-Xue decoction inhibits intestinal epithelial cell apoptosis in CCl₄-induced liver fibrosis[J]. Cell Physiol Biochem, 2017, 44(1): 333-344. DOI: 10.1159/000484904
[9]	LI Y, TANG L, GUO L, et al. CXCL13-mediated recruitment of intrahepatic CXCR5+CD8+ T cells favors viral control in chronic HBV infection[J]. J Hepatol, 2020, 72(3): 420-430. DOI: 10.1016/j.jhep.2019.09.031
[10]	GONG H, LI LP. Research advances of portal vein thrombosis in nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2020, 36(9): 2107-2110. (in Chinese. DOI: 10.3969/j.issn.1001-5256.2020.09.045 龚航, 李良平. 非酒精性脂肪性肝病并发门静脉血栓的研究进展[J]. 临床肝胆病杂志, 2020, 36(9): 2107-2110. DOI: 10.3969/j.issn.1001-5256.2020.09.045
[11]	CHU H, DUAN Y, LANG S, et al. The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease[J]. J Hepatol, 2020, 72(3): 391-400. DOI: 10.1016/j.jhep.2019.09.029
[12]	SHE S, WU X, ZHENG D, et al. PSMP/MSMP promotes hepatic fibrosis through CCR2 and represents a novel therapeutic target[J]. J Hepatol, 2020, 72(3): 506-518. DOI: 10.1016/j.jhep.2019.09.033
[13]	DAI KM. Jiang Chunhua's experience in using Xiayuxue decoction[J]. Shanxi J Tradit Chin Med, 2012, 28(1): 4-6. (in Chinese. https://www.cnki.com.cn/Article/CJFDTOTAL-SHIX201201003.htm 戴克敏. 姜春华运用下瘀血汤的经验[J]. 山西中医, 2012, 28(1): 4-6. https://www.cnki.com.cn/Article/CJFDTOTAL-SHIX201201003.htm
[14]	LIU C, CAI J, CHENG Z, et al. Xiayuxue decoction reduces renal injury by promoting macrophage apoptosis in hepatic cirrhotic rats[J]. Genet Mol Res, 2015, 14(3): 10760-10773. DOI: 10.4238/2015.September.9.15
[15]	WU L, ZHANG J, MA WT, et al. Xiayuxue decoction inhibits methionine-choline-deficient-induced nonalcoholic steatohepatitis in mice[J/CD]. Chin J Liver Dis (Electronic Version), 2018, 10(3): 48-55. (in Chinese. 吴柳, 张洁, 马文婷, 等. 下瘀血汤对MCD诱导小鼠非酒精性脂肪性肝炎干预作用研究[J/CD]. 中国肝脏病杂志(电子版), 2018, 10(3): 48-55.
[16]	SHEN DX, MA WT, WU L, et al. Mechanism of Xiayuxue decoction on improving liver fibrosis by inhibiting pancreatic macrophage infiltration[J]. Acta Univ Tradit Med Sin Pharmacol Shanghai, 2019, 33(2): 73-80. (in Chinese. https://www.cnki.com.cn/Article/CJFDTOTAL-SHZD201902015.htm 沈东晓, 马文婷, 吴柳, 等. 下瘀血汤抑制胰腺巨噬细胞浸润改善肝纤维化的机制研究[J]. 上海中医药大学学报, 2019, 33(2): 73-80. https://www.cnki.com.cn/Article/CJFDTOTAL-SHZD201902015.htm
[17]	NAHARI E, RAZI M. Silymarin amplifies apoptosis in ectopic endometrial tissue in rats with endometriosis; implication on growth factor GDNF, ERK1/2 and Bcl-6b expression[J]. Acta Histochem, 2018, 120(8): 757-767. DOI: 10.1016/j.acthis.2018.08.003
[18]	KAWAMOTO K, YAGI M, STÖVER T, et al. Hearing and hair cells are protected by adenoviral gene therapy with TGF-beta1 and GDNF[J]. Mol Ther, 2003, 7(4): 484-492. DOI: 10.1016/S1525-0016(03)00058-3
[19]	NENCINI S, RINGUET M, KIM DH, et al. GDNF, Neurturin, and Artemin activate and sensitize bone afferent neurons and contribute to inflammatory bone pain[J]. J Neurosci, 2018, 38(21): 4899-4911. DOI: 10.1523/JNEUROSCI.0421-18.2018

Relative Articles

[1]	Lixia MA, Xinhuan WEI, Zhenhuan CAO, Jing ZHANG. Association between serum endothelial cell-specific molecule 1 and cirrhotic cardiomyopathy[J]. Journal of Clinical Hepatology, 2024, 40(6): 1156-1161. doi: 10.12449/JCH240614
[2]	Linqi HOU, Zhiyi WANG, Xin ZHAO, Jie ZHANG, Wenting MA, Xuling LIU, Wei ZHANG, Le TAO, Cheng LIU, Liu WU. Therapeutic effect of Xiayuxue decoction on a mouse model of nonalcoholic fatty liver disease induced by high-fat diet and its mechanism[J]. Journal of Clinical Hepatology, 2024, 40(4): 712-719. doi: 10.12449/JCH240412
[3]	Xin ZHAO, Zhiyi WANG, Le TAO, Guangyue YANG, Wei ZHANG, Liu WU, Wenting MA, Qian CHEN, Xuling LIU, Cheng LIU. Effect of Xiayuxue Decoction against renal injury in mice with non-alcoholic fatty liver disease and its mechanism[J]. Journal of Clinical Hepatology, 2024, 40(11): 2213-2220. doi: 10.12449/JCH241114
[4]	Liang ZHANG, Hao LI, Shanhong TANG. Thoughts on the diagnosis and treatment of hepatic encephalopathy associated with blood ammonia in liver cirrhosis[J]. Journal of Clinical Hepatology, 2023, 39(12): 2942-2945. doi: 10.3969/j.issn.1001-5256.2023.12.028
[5]	Haoyi WANG, Jingyin MAI, Jian PING, Yang CHENG. Effect of serum containing Huangqi decoction on the proliferation, migration, and tubulogenesis of rat liver sinusoidal endothelial cells induced by vascular endothelial growth factor and its mechanism of action[J]. Journal of Clinical Hepatology, 2022, 38(10): 2279-2285. doi: 10.3969/j.issn.1001-5256.2022.10.015
[6]	Zunlan ZHOU, Lina YANG, Qingqing LI, Hong WANG. Research advances in the early predictive factors for non-neoplastic portal vein thrombosis in liver cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(9): 2150-2154. doi: 10.3969/j.issn.1001-5256.2022.09.039
[7]	Chen ChengLiang, Song Wei, Meng XiuNa, Tian Xing, Jiao Jian. Significance of serum ischemia-modified albumin level in evaluating liver function in patients with liver cirrhosis of various causes[J]. Journal of Clinical Hepatology, 2016, 32(8): 1534-1537. doi: 10.3969/j.issn.1001-5256.2016.08.020
[8]	Wang HongJie, Zhou JingJing, Sun Ying, Wen XiaoYu, Jin QingLong. One case of poikiloderma vasculare atrophicans with cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(3): 441-442. doi: 10.3969/j.issn.1001-5256.2015.03.031
[9]	Hu YuLin, Quan XiangLan. Research state and prospect of hyponatremia in cirrhosis[J]. Journal of Clinical Hepatology, 2011, 27(3): 330-332.
[10]	Wang ShunDa, Dang ShuangSuo, Cheng YanAn, Gao Ning, Zhang Xin, Jia XiaoLi. The expression of TPO and GM - CSF in the marrow fluid and the relations with peripheral blood cells of liver cirrhosis patients[J]. Journal of Clinical Hepatology, 2010, 26(5): 531-533.
[11]	Gao YuanZheng, Jia SuHua, Liu YuYing, Zhang ShouMin, Wang Yan, Zhao LianFeng, Wei XingHui. Efficacy of allogeneic umbilical cord blood stem cell transplantation for treatment of decompensated cirrhosis[J]. Journal of Clinical Hepatology, 2010, 26(6): 613-614+617.
[16]	Chen HongBin, Zhang YaDong, Huang Yue, Chen XiaoChun. Clinical significance of determination plasma neuropeptide Y in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2001, 17(2): 103-104.

Supplements(0)

Cited By

Cited by

Periodical cited type(33)

1.	张刘璐，吕俊，刘迎春，尧麒，汪静，刘勇. 原发性肝细胞癌不同类型MRI征象分析. 中国CT和MRI杂志. 2023(05): 85-87 .
2.	游家生，吕秀金，郭伟娟. 动态增强MRI与CT对乙型肝炎肝硬化背景下原发性肝癌的诊断价值. 海南医学. 2022(01): 79-82 .
3.	郑蕊，李秀芹，代笑梅. 术前彩色多普勒超声血流参数对原发性与转移性肝癌的鉴别诊断价值. 癌症进展. 2022(18): 1926-1929 .
4.	麦乃全，温惠澄，梁础群. 磁共振弥散加权成像联合动态增强技术对肝内实性结节的诊断价值. 医疗装备. 2021(06): 16-18 .
5.	贺全富. MSCT灌注成像联合DCE-MRI在肝硬化结节与小肝癌鉴别诊断中的应用. 医药论坛杂志. 2021(06): 126-129 .
6.	王梅英. 肝细胞性肝癌的超声影像学表现与病理特征. 中国继续医学教育. 2021(15): 124-128 .
7.	马亦飞. 超声造影联合彩色多普勒超声在鉴别诊断小体积肝脏占位性病变中的价值分析. 现代实用医学. 2021(06): 778-780 .
8.	李芳，任晓琪. 彩色多普勒超声诊断肝胆管细胞癌和肝细胞肝癌的临床特征. 临床医学研究与实践. 2021(22): 120-121+127 .
9.	陈孝卫，黄武强，蔡道修. miR-1246和NFIB在肝癌组织中的表达及其与肝癌预后的关系. 东南大学学报(医学版). 2021(06): 772-778 .
10.	陈家诚，陈小菁，庄春雨，刘富金，罗是是，陈良，武金才，周开伦. 肝内脾异位结节1例报告. 临床肝胆病杂志. 2020(05): 1131-1133 . 本站查看
11.	韩利峰，唐秀丽，程秀莲，赵娜. 原发性肝癌血供特点与病理学特性的相关性研究. 中西医结合肝病杂志. 2020(03): 258-260+264 .
12.	贺莉，乔龙虎，张振奇. 高浓度碘对比剂在肝癌64排螺旋CT动态增强扫描中的效能分析. 中西医结合肝病杂志. 2020(05): 441-443 .
13.	秦书敏，刘亚良，黄光建，王萌，应可明. 原发性肝细胞癌患者多层螺旋CT及MRI临床诊断价值分析. 中国CT和MRI杂志. 2020(12): 77-79 .
14.	刘洋，寻航，李修奎，姚鹏飞. 螺旋CT灌注成像与超声超微细血流成像在评估肝癌介入术后活性病灶血供中的应用比较. 中国CT和MRI杂志. 2019(04): 86-88+153 .
15.	卓涛，陈海燕，陈冬梅，李坚. 超声造影在微小肝细胞肝癌诊断中的应用价值. 临床和实验医学杂志. 2019(07): 766-769 .
16.	梁伟强，王猛. 术前肝脏储备功能评估的最新研究进展. 新医学. 2019(04): 229-233 .
17.	祁生平，杨云. MRI和CT影像学检查对肝脏疾病术前诊断及术后恢复的评估. 中国医学装备. 2019(06): 49-52 .
18.	高德军，韦章诚，陈首名. 1.5T核磁共振动态增强扫描在肝癌分期评估中的临床应用. 实用癌症杂志. 2019(07): 1204-1207 .
19.	王家友，赵勇，伍小勇. 普美显磁共振对早期肝硬化合并小肝癌的诊断价值. 中国CT和MRI杂志. 2019(08): 92-95 .
20.	李秀浓，田小银. 全程护患沟通护理在肝癌行肝叶切除术患者中的应用效果研究. 中国现代药物应用. 2019(16): 157-159 .
21.	陈晓丽，邝菲，李琪红，周冉. 多期增强螺旋CT与超声造影对原发性肝癌的影像学诊断效能对照分析. 中国CT和MRI杂志. 2019(11): 77-80 .
22.	周婉，金良红. 超声造影及CT定量检测在肝癌介入治疗后疗效评估中的应用. 肝脏. 2019(12): 1422-1425 .
23.	房海燕，高敏，徐亚运. 经射频消融治疗后复发的微小肝癌患者磁共振图像特点分析. 中国肝脏病杂志(电子版). 2018(01): 50-53 .
24.	李黎，任思桦，骆成俊，袁涛. 64-MDCT扫描中不同浓度碘对比剂对肝癌不同时相的检出率与增强效果. 局解手术学杂志. 2018(01): 61-64 .
25.	刘钊，马文婷，张鹏飞，黎金葵，肖建喜，雷军强. 肝细胞癌分子影像诊断进展. 临床肝胆病杂志. 2018(04): 872-876 . 本站查看
26.	潘奇，罗春海，马婉玲，曲原飞，王建如，陈琳. 血管内皮生长因子C靶向分子探针在肝细胞癌大鼠模型中的特异性磁共振成像及临床意义. 临床肝胆病杂志. 2018(07): 1492-1496 . 本站查看
27.	陈琪萍，林苏，史震山，朱月永，李友炳. 钆塞酸二钠增强磁共振成像与超声在肝细胞癌筛查中的成本效益分析. 临床肝胆病杂志. 2018(09): 1917-1920 . 本站查看
28.	罗心晨，周友乾. 从增加高危人群定期筛查依从性谈原发性肝癌早期诊断. 临床肝胆病杂志. 2018(08): 1788-1792 . 本站查看
29.	吴杨，施丽丽，房海燕，高敏. 原发性肝癌的CT灌注参数特征及肝脏储备功能评估价值. 中国现代普通外科进展. 2018(04): 309-310 .
30.	张琳. 多排螺旋CT肝脏多期增强扫描对鉴别肝脏肿瘤的意义探讨. 影像研究与医学应用. 2018(21): 105-106 .
31.	刘国. 利用超声鉴别诊断肝细胞肝癌、肝胆管细胞癌的临床价值. 影像研究与医学应用. 2018(22): 150-151 .
32.	张志平，陈飞，戴真煜，姚立正，董从松，刘洋，潘文艳. 肝细胞癌综合治疗后复发的小肝癌患者MRI平扫和动态增强各序列图像表现分析. 医学影像学杂志. 2018(11): 1868-1871 .
33.	黄超，胡海华，郑银元. 不同影像方法测量原发性肝癌大小的效果比较. 中国现代医生. 2018(28): 125-128 .

Other cited types(10)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(4) / Tables(7)

Get Citation

PDF

XML

Article Metrics

Article views (1080) PDF downloads(66)

Mechanism of action of Xiayuxue decoction in inhibiting liver fibrosis by regulating glial cell line-derived neurotrophic factor

DOI: 10.3969/j.issn.1001-5256.2021.03.015